First-line antibiotics for uncomplicated UTI remain more effective than fluoroquinolones and beta-lactams in a retrospective ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for improved treatment. UTIs are one of the most prevalent bacterial infections ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

New insights into what causes the painful and disruptive symptoms of urinary tract infections (UTIs) could offer hope for ...

Most of Dr. Leah Schrupp’s patients know it. So do most of Dr. Erin Knudtson’s patients. If they visit their doctor with a runny nose, chest cold or the usual flu symptoms, they ...

The condition can be tricky though, since older adults’ bladders are often colonized with bacteria that will show in a test but are not causing symptoms.

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Urinary frequency ... systemic signs of infection; further evaluation is necessary.2, 3 Vaginal estrogen reduces recurrence by improving mucosal thickness, immune function, and vaginal flora, and ...

AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

Frequent UTIs are not just a localised problem but may be influenced by the health of your gut microbiome. By focusing on gut ...